pre-update Archives

Blog

Top 10 Benefits to Integrating the Simcyp PBPK Simulator into your Drug Development Program

Per US FDA’s recent paper on the topic, Physiologically based Pharmacokinetic (PBPK) modeling & simulation…

CertaraJune 22, 2021

Blog

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence…

CertaraJune 18, 2021

Blog

Watershed Moment for the Future of Cell Therapy Development – FDA Advisory Committee Meeting

Every FDA Advisory Committee meeting is unique, and the Cellular, Tissue, and Gene Therapies Advisory…

CertaraJune 15, 2021

Brochure

Drive Impactful Science from Bench to Market

Learn how Certara drives impactful science.

CertaraJune 14, 2021

On-Demand Webinar

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function…

CertaraJune 11, 2021

On-Demand Webinar

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function…

CertaraJune 11, 2021

Video

Your First Choice in Complex Biologics Drug Development

The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…

CertaraJune 1, 2021

On-Demand Webinar

De-risk your program with evidence-based secondary pharmacology insights

Safety issues account for about a quarter of the attrition in drug projects and can…

CertaraMay 28, 2021

On-Demand Webinar

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

CertaraMay 26, 2021

On-Demand Webinar

Strengths and opportunities for HTAs and market access in Europe through case studies

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…

CertaraMay 26, 2021

pre-update

Top 10 Benefits to Integrating the Simcyp PBPK Simulator into your Drug Development Program

Preparing for High Stakes Meetings; How to Best Convey a New Drug’s Value to Payers

Watershed Moment for the Future of Cell Therapy Development – FDA Advisory Committee Meeting

Drive Impactful Science from Bench to Market

Three Pathways have emerged in Innovative Access Agreements

Outcomes Based Agreements

Your First Choice in Complex Biologics Drug Development

De-risk your program with evidence-based secondary pharmacology insights

Stakeholder perspectives: current and potential benefits

Strengths and opportunities for HTAs and market access in Europe through case studies

Newsletter sign up

Quick links

Solutions

Contact